Stryker Corp Stock Price, News & Analysis

Stryker (NYSE:SYK) has launched the Sync Badge, a hands-free wearable communication device designed to enhance collaboration in patient care environments. The device allows care team members to use voice commands to connect with colleagues across units and roles.

Key features include:

• Voice activation using 'Okay Vocera' wake word
• Dedicated panic button for emergency assistance
• Do Not Disturb mode with urgent call breakthrough
• Integration with EHR, nurse call systems, and medical devices

The launch aims to address ongoing nursing shortages and unpredictable healthcare environments by simplifying workflows and improving communication efficiency.

Stryker (NYSE: SYK) has completed the acquisition of Inari Medical, a company specializing in venous thromboembolism (VTE) clot removal solutions. The acquisition provides Stryker entry into the fast-growing peripheral vascular segment. The transaction was completed through a cash tender offer at $80.00 per share, with approximately 81.69% (48,504,444 shares) of Inari's outstanding shares validly tendered.

Inari's product portfolio, which includes the FlowTriever System for pulmonary embolism treatment and the ClotTriever System for peripheral vessel thrombectomy, complements Stryker's Neurovascular business. Following the merger completion on February 19, 2025, Inari has become a wholly owned subsidiary of Stryker and will be delisted from the Nasdaq Global Select Market.

Stryker (NYSE:SYK) has announced its participation in Citi's 2025 Unplugged Medtech and Life Sciences Access Day. The event will take place on Thursday, February 27, 2025 at Citigroup Headquarters in New York.

The company's management will deliver a presentation scheduled for 12:15 p.m. Eastern Time. Investors and interested parties can access a simultaneous webcast of the presentation through Stryker's website. The presentation will also be archived on the company's Investor Relations page for future reference.

Stryker (NYSE:SYK) announced that Allan Golston will not seek re-election at the company's 2025 Annual Meeting of Shareholders, scheduled for May 8, 2025. Golston served on Stryker's Board of Directors for 14 years since 2011, including roles as independent Lead Director (2016-2022), and positions on the Governance and Nominating Committee, while also chairing the Compensation and Human Capital and Audit Committees.

Golston, who has been President of the United States Program at the Bill & Melinda Gates Foundation since 2006, brought extensive healthcare industry experience to Stryker's board. His background includes positions as a certified public accountant and hospital finance executive. He also serves as a director at Harley-Davidson.

Stryker (NYSE:SYK) has announced its Board of Directors' declaration of a quarterly dividend of $0.84 per share. The dividend will be payable on April 30, 2025, to shareholders of record as of the close of business on March 31, 2025. This dividend represents a 5.0% increase compared to the prior year while remaining unchanged from the previous quarter.

RevBio has been granted its 10th U.S. patent (12,178,937) for the TETRANITE® bone adhesive technology, expanding protection for injectable mineral-organic structural bone adhesive compositions containing alpha tricalcium phosphate. This complements their existing patent 11,638,777 for bone fracture repair methods.

TETRANITE® is notable as the only patented bone adhesive containing phosphoserine, an organic compound linked to bone regeneration. RevBio acquired exclusive worldwide patent rights from Stryker (NYSE: SYK) for six patent families, providing protection through 2033. Since 2016, RevBio has filed fourteen Patent Cooperation Treaty applications, with protection extending to 2043 across multiple jurisdictions including the U.S., EU, Canada, Australia, Japan, and China.

Stryker (NYSE:SYK) has announced a definitive agreement to sell its U.S. spinal implants business to Viscogliosi Brothers, , which will create a new company called VB Spine, . The transaction includes a binding offer to acquire Stryker's spinal implants business in France and plans to sell related international operations.

After closing, VB Spine will become a strategic partner to Stryker with exclusive access to Mako Spine and Copilot for use with VB Spine's implants. The deal aims to enhance focus for both companies and is expected to achieve faster growth and deliver greater value for stakeholders.

The transaction is expected to close in the U.S. in the first half of 2025, subject to customary closing conditions. Barings, will serve as an investor and financial partner to Viscogliosi Brothers in this transaction.

Stryker (NYSE: SYK) announced significant leadership changes as Glenn S. Boehnlein will retire from his position as Vice President, Chief Financial Officer after 22 years with the company. Preston Wells, currently serving as Group CFO for Stryker's Orthopaedics Group, will take over as Vice President, Chief Financial Officer effective April 1, 2025.

Wells brings extensive experience from various finance roles at Stryker, including leadership in Investor Relations, Enterprise Financial Planning & Analysis, and sales finance operations. His current role involves collaboration with Joint Replacement, Trauma & Extremities, Spine, and Digital, Robotics, and Enabling Technologies teams. Before joining Stryker, Wells accumulated 17 years of senior accounting and financial management experience at Dialight and Johnson & Johnson. He holds a bachelor's in accounting from Bucknell University and an MBA in Supply Chain Management from Lehigh University.

Stryker (NYSE:SYK) reported strong Q4 and full-year 2024 results, with Q4 reported net sales increasing 10.7% to $6.4 billion and full-year sales rising 10.2% to $22.6 billion. The company achieved organic net sales growth of 10.2% for both periods.

Q4 adjusted EPS increased 15.9% to $4.01, while full-year adjusted EPS grew 15.0% to $12.19. However, reported EPS decreased 52.7% to $1.41 in Q4 and 5.9% to $7.76 for the full year, primarily due to $818 million in non-cash charges for goodwill and other impairments related to the Spine business.

For 2025, Stryker expects organic net sales growth between 8.0% and 9.0%, with adjusted EPS projected at $13.45-$13.70. The company anticipates closing the Inari acquisition in February 2025, expected to contribute approximately $590 million in sales for the stub period.